# Neoadjuvant Ivonescimab and Chemotherapy in Resectable Esophageal Cancer

> **NCT06814158** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Tianjin Medical University Cancer Institute and Hospital** · enrollment: 57 (estimated)

## Conditions studied

- Esophageal Squamour Cell Cancer

## Interventions

- **DRUG:** Ivonescimab Combined With Chemotherapy

## Key facts

- **NCT ID:** NCT06814158
- **Lead sponsor:** Tianjin Medical University Cancer Institute and Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-03-01
- **Primary completion:** 2026-07-30
- **Final completion:** 2026-12-31
- **Target enrollment:** 57 (ESTIMATED)
- **Last updated:** 2025-02-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06814158

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06814158, "Neoadjuvant Ivonescimab and Chemotherapy in Resectable Esophageal Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06814158. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*